Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 2,322 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 2,322 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total transaction of $558,510.66. Following the completion of the transaction, the chief executive officer owned 216,828 shares in the company, valued at $52,153,638.84. The trade was a 1.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Wednesday, January 28th, Steven Leonard Chapman sold 3,648 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $866,983.68.
• On Wednesday, January 21st, Steven Leonard Chapman sold 1,590 shares of Natera stock. The shares were sold at an average price of $235.00, for a total value of $373,650.00.
• On Tuesday, January 20th, Steven Leonard Chapman sold 71,932 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $16,885,317.68.
• On Friday, January 2nd, Steven Leonard Chapman sold 3,848 shares of Natera stock. The stock was sold at an average price of $229.08, for a total value of $881,499.84.
• On Monday, December 1st, Steven Leonard Chapman sold 4,400 shares of Natera stock. The shares were sold at an average price of $238.07, for a total value of $1,047,508.00.
• On Monday, November 3rd, Steven Leonard Chapman sold 160,703 shares of Natera stock. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88.

Natera Stock Down 1.9%

NASDAQ:NTRA opened at $231.48 on Friday. The firm’s fifty day simple moving average is $235.90 and its 200 day simple moving average is $193.29. The stock has a market cap of $32.02 billion, a P/E ratio of -101.08 and a beta of 1.62. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Hedge funds have recently bought and sold shares of the company. D.A. Davidson & CO. purchased a new stake in Natera during the 4th quarter valued at about $570,000. Kestra Private Wealth Services LLC bought a new position in shares of Natera in the fourth quarter worth approximately $271,000. Pictet Asset Management Holding SA grew its holdings in shares of Natera by 2.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 50,883 shares of the medical research company’s stock valued at $11,657,000 after buying an additional 1,447 shares during the last quarter. Huntleigh Advisors Inc. grew its holdings in shares of Natera by 5.3% during the fourth quarter. Huntleigh Advisors Inc. now owns 11,412 shares of the medical research company’s stock valued at $2,614,000 after buying an additional 570 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Natera by 19.4% during the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock valued at $100,538,000 after acquiring an additional 71,355 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research note on Monday, January 12th. Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Piper Sandler boosted their target price on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Wells Fargo & Company increased their price target on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $249.20.

More Natera News

Here are the key news stories impacting Natera this week:

• Negative Sentiment: CFO Michael Burkes Brophy sold a total of 5,064 shares across Jan. 27–29 for roughly $1.19M (transactions at ~$240.53, $237.56 and $230.40); his holdings fell by ~3% but he still holds ~59k shares. CFO Form 4
• Negative Sentiment: CEO Steven L. Chapman sold 5,970 shares across Jan. 27–28 for roughly $1.43M (avg ~$237–240); his stake decreased ~1–2% and he still owns ~213k shares. CEO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold multiple tranches (combined ~3,925 shares, ~ $0.94M), each reducing holdings by under 1%. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.